Bio Accounts Payable from 2010 to 2024
| TECH Stock | USD 75.38 0.51 0.68% |
Accounts Payable | First Reported 1989-09-30 | Previous Quarter 38 M | Current Value 31.6 M | Quarterly Volatility 27.4 M |
Check Bio Techne financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Techne's main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.3 M, Total Revenue of 1.2 B or Gross Profit of 808.2 M, as well as many indicators such as Price To Sales Ratio of 6.9, Dividend Yield of 0.0042 or PTB Ratio of 6.78. Bio financial statements analysis is a perfect complement when working with Bio Techne Valuation or Volatility modules.
Bio | Accounts Payable |
Latest Bio Techne's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Bio Techne Corp over the last few years. An accounting item on the balance sheet that represents Bio Techne obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Bio Techne Corp are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Bio Techne's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Techne's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Bio Accounts Payable Regression Statistics
| Arithmetic Mean | 35,202,293 | |
| Geometric Mean | 23,580,612 | |
| Coefficient Of Variation | 62.03 | |
| Mean Deviation | 17,230,180 | |
| Median | 33,865,000 | |
| Standard Deviation | 21,837,383 | |
| Sample Variance | 476.9T | |
| Range | 70.6M | |
| R-Value | 0.49 | |
| Mean Square Error | 390.6T | |
| R-Squared | 0.24 | |
| Significance | 0.06 | |
| Slope | 2,389,092 | |
| Total Sum of Squares | 6676.2T |
Bio Accounts Payable History
About Bio Techne Financial Statements
Investors use fundamental indicators, such as Bio Techne's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Bio Techne's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 38 M | 39.9 M |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out the analysis of Bio Techne Correlation against competitors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.